NFE2L2 and non-small cell lung carcinoma: The combinational use of EGCG with metformin, a classical antidiabetic drug, stimulated intracellular ROS accumulation induced by EGCG (100 μM) through the modulation of Sirtuin 1-dependent deacetylation on NRF2, thus augmenting the anticancer effect of EGCG in NSCLC treatment [204].